AGIOS PHARMACEUTICALS, INC. Quarterly Operating Income (Loss) in USD from Q1 2012 to Q3 2024

Taxonomy & unit: us-gaap: USD
Description: The net result for the period of deducting operating expenses from operating revenues.
Summary: Agios Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2012 to Q3 2024.
Agios Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$103M, a 1.9% decline year-over-year.
Agios Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$407M, a 5.88% decline year-over-year.
Agios Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$391M, a 0.63% decline from 2022.
Agios Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$389M, a 2.81% decline from 2021.
Agios Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$378M, a 12.7% decline from 2020.

Operating Income (Loss), Trailing 12 Months (USD)

Operating Income (Loss), Quarterly (USD)

Operating Income (Loss), YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q3 2024	-$407M	-$103M	-$1.91M	-1.9%	Jul 1, 2024	Sep 30, 2024	10-Q	2024-10-31
Q2 2024	-$405M	-$106M	-$12.1M	-12.9%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-01
Q1 2024	-$393M	-$92.1M	-$1.46M	-1.61%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-02
Q4 2023	-$391M	-$106M	-$7.11M	-7.16%	Oct 1, 2023	Dec 31, 2023	10-K	2024-02-15
Q3 2023	-$384M	-$101M	-$9.81M	-10.8%	Jul 1, 2023	Sep 30, 2023	10-Q	2024-10-31
Q2 2023	-$375M	-$93.7M	+$3.94M	+4.04%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-01
Q1 2023	-$379M	-$90.6M	+$10.5M	+10.4%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-02
Q4 2022	-$389M	-$99.2M	+$5.66M	+5.4%	Oct 1, 2022	Dec 31, 2022	10-K	2024-02-15
Q3 2022	-$395M	-$91.1M	+$62K	+0.07%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-02
Q2 2022	-$395M	-$97.6M	-$6.42M	-7.04%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-03
Q1 2022	-$388M	-$101M	-$9.93M	-10.9%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-04
Q4 2021	-$378M	-$105M	-$12.4M	-13.4%	Oct 1, 2021	Dec 31, 2021	10-K	2024-02-15
Q3 2021	-$366M	-$91.2M	-$10.9M	-13.5%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-03
Q2 2021	-$355M	-$91.2M	-$7.96M	-9.56%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-04
Q1 2021	-$347M	-$91.2M	-$4.19M	-4.81%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-05
Q4 2020	-$343M	-$92.4M	+$13.5M	+12.7%	Oct 1, 2020	Dec 31, 2020	10-K	2021-02-25
Q3 2020	-$357M	-$80.3M	+$28.8M	+26.4%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-03
Q2 2020	-$385M	-$83.3M	+$30.6M	+26.9%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-07-29
Q1 2020	-$416M	-$87M	+$10.5M	+10.7%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-04-29
Q4 2019	-$426M	-$106M	-$9.57M	-9.94%	Oct 1, 2019	Dec 31, 2019	10-K	2021-02-25
Q3 2019	-$417M	-$109M	-$9.9M	-9.98%	Jul 1, 2019	Sep 30, 2019	10-K	2021-02-25
Q2 2019	-$407M	-$114M	-$40.9M	-56.1%	Apr 1, 2019	Jun 30, 2019	10-K	2021-02-25
Q1 2019	-$366M	-$97.5M	-$3.47M	-3.69%	Jan 1, 2019	Mar 31, 2019	10-K	2021-02-25
Q4 2018	-$362M	-$96.4M	-$6.23M	-6.91%	Oct 1, 2018	Dec 31, 2018	10-K	2020-02-19
Q3 2018	-$356M	-$99.2M	-$20.1M	-25.5%	Jul 1, 2018	Sep 30, 2018	10-K	2020-02-19
Q2 2018	-$336M	-$72.9M	+$11.7M	+13.8%	Apr 1, 2018	Jun 30, 2018	10-K	2020-02-19
Q1 2018	-$348M	-$94M	-$27M	-40.2%	Jan 1, 2018	Mar 31, 2018	10-K	2020-02-19
Q4 2017	-$321M	-$90.1M	-$32.7M	-57%	Oct 1, 2017	Dec 31, 2017	10-K	2019-02-14
Q3 2017	-$288M	-$79M	-$15.5M	-24.4%	Jul 1, 2017	Sep 30, 2017	10-K	2019-02-14
Q2 2017	-$273M	-$84.6M	-$28.1M	-49.8%	Apr 1, 2017	Jun 30, 2017	10-K	2019-02-14
Q1 2017	-$244M	-$67M	-$43.5M	-184%	Jan 1, 2017	Mar 31, 2017	10-K	2019-02-14
Q4 2016	-$201M	-$57.4M	-$16.5M	-40.4%	Oct 1, 2016	Dec 31, 2016	10-K	2018-02-14
Q3 2016	-$184M	-$63.5M	-$23M	-56.9%	Jul 1, 2016	Sep 30, 2016	10-K	2018-02-14
Q2 2016	-$161M	-$56.5M	-$24.3M	-75.7%	Apr 1, 2016	Jun 30, 2016	10-K	2018-02-14
Q1 2016	-$137M	-$23.6M	-$18.4M	-354%	Jan 1, 2016	Mar 31, 2016	10-K	2018-02-14
Q4 2015	-$119M	-$40.9M	-$14.2M	-53%	Oct 1, 2015	Dec 31, 2015	10-K	2017-02-16
Q3 2015	-$105M	-$40.5M	-$43.7M	-1362%	Jul 1, 2015	Sep 30, 2015	10-K	2017-02-16
Q2 2015	-$60.8M	-$32.1M	-$13.8M	-75.3%	Apr 1, 2015	Jun 30, 2015	10-K	2017-02-16
Q1 2015	-$47M	-$5.2M	+$7.09M	+57.7%	Jan 1, 2015	Mar 31, 2015	10-K	2017-02-16
Q4 2014	-$54.1M	-$26.7M	-$14.5M	-118%	Oct 1, 2014	Dec 31, 2014	10-K	2016-02-26
Q3 2014	-$39.6M	$3.21M	+$14.3M		Jul 1, 2014	Sep 30, 2014	10-K	2016-02-26
Q2 2014	-$53.9M	-$18.3M	-$9.8M	-115%	Apr 1, 2014	Jun 30, 2014	10-K	2016-02-26
Q1 2014	-$44.1M	-$12.3M	-$5.24M	-74.3%	Jan 1, 2014	Mar 31, 2014	10-K	2016-02-26
Q4 2013	-$38.9M	-$12.2M	-$5.74M	-88.4%	Oct 1, 2013	Dec 31, 2013	10-K	2015-02-24
Q3 2013	-$33.1M	-$11.1M	-$5.96M	-117%	Jul 1, 2013	Sep 30, 2013	10-K	2015-02-24
Q2 2013	-$27.2M	-$8.53M	-$2.4M	-39.2%	Apr 1, 2013	Jun 30, 2013	10-K	2015-02-24
Q1 2013	-$24.8M	-$7.05M	-$1.78M	-33.9%	Jan 1, 2013	Mar 31, 2013	10-K	2015-02-24
Q4 2012	-$23M	-$6.5M			Oct 1, 2012	Dec 31, 2012	10-K	2014-03-18
Q3 2012		-$5.11M			Jul 1, 2012	Sep 30, 2012	10-K	2014-03-18
Q2 2012		-$6.12M			Apr 1, 2012	Jun 30, 2012	10-K	2014-03-18
Q1 2012		-$5.26M			Jan 1, 2012	Mar 31, 2012	10-K	2014-03-18

* An asterisk sign (*) next to the value indicates that the value is likely invalid.